Article info
PDFShort Report
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- ↵a 732-235-7701 hk553{at}cinj.rutgers.edu
- ↵b jeffery.russell{at}immunocore.com
- ↵c ohamid{at}theangelesclinic.org
- ↵d sbhatia{at}uw.edu
- ↵e patrick.terheyden{at}uksh.de
- ↵f dangelos{at}mskcc.org
- ↵g kshih{at}tnonc.com
- ↵h celeste.lebbe{at}sls.aphp.fr
- ↵i michelemilella{at}hotmail.com
- ↵j isaac.brownell{at}nih.gov
- ↵k karl.lewis{at}ucdenver.edu
- ↵l jochen_lorch{at}dfci.harvard.edu
- ↵m anja.von.heydebreck{at}merckgroup.com
- ↵n meliessa.hennessy{at}emdserono.com
- ↵o pnghiem{at}uw.edu
Citation
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Publication history
- Received October 26, 2017
- Accepted December 12, 2017
- First published January 19, 2018.
Online issue publication
February 09, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.